193 related articles for article (PubMed ID: 37865722)
41. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
42. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
[TBL] [Abstract][Full Text] [Related]
43. Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
Husain H; Pavlick DC; Fendler BJ; Madison RW; Decker B; Gjoerup O; Parachoniak CA; McLaughlin-Drubin M; Erlich RL; Schrock AB; Frampton GM; Das Thakur M; Oxnard GR; Tukachinsky H
JCO Precis Oncol; 2022 Oct; 6():e2200261. PubMed ID: 36265119
[TBL] [Abstract][Full Text] [Related]
44. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
[TBL] [Abstract][Full Text] [Related]
45. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
Fiala C; Diamandis EP
Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
[TBL] [Abstract][Full Text] [Related]
46. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.
Addanki S; Meas S; Sarli VN; Singh B; Lucci A
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887191
[TBL] [Abstract][Full Text] [Related]
47. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
[TBL] [Abstract][Full Text] [Related]
48. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
49.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
50. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
51. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
52. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
Moldogazieva NT; Zavadskiy SP; Terentiev AA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
[TBL] [Abstract][Full Text] [Related]
53. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Herberts C; Annala M; Sipola J; Ng SWS; Chen XE; Nurminen A; Korhonen OV; Munzur AD; Beja K; Schönlau E; Bernales CQ; Ritch E; Bacon JVW; Lack NA; Nykter M; Aggarwal R; Small EJ; Gleave ME; ; Quigley DA; Feng FY; Chi KN; Wyatt AW
Nature; 2022 Aug; 608(7921):199-208. PubMed ID: 35859180
[TBL] [Abstract][Full Text] [Related]
54. The Different Facets of Liquid Biopsy: A Kaleidoscopic View.
Eslami-S Z; Cortés-Hernández LE; Cayrefourcq L; Alix-Panabières C
Cold Spring Harb Perspect Med; 2020 Jun; 10(6):. PubMed ID: 31548226
[TBL] [Abstract][Full Text] [Related]
55. Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening.
Kojic M; Maybury MK; Waddell N; Koufariotis LT; Addala V; Millar A; Wood S; Pearson JV; Hansford JR; Hassall T; Wainwright BJ
Neuro Oncol; 2023 Aug; 25(8):1507-1517. PubMed ID: 36757207
[TBL] [Abstract][Full Text] [Related]
56. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
[TBL] [Abstract][Full Text] [Related]
57. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
[No Abstract] [Full Text] [Related]
58. ctDNA as a cancer biomarker: A broad overview.
Pessoa LS; Heringer M; Ferrer VP
Crit Rev Oncol Hematol; 2020 Nov; 155():103109. PubMed ID: 33049662
[TBL] [Abstract][Full Text] [Related]
59. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
60. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
